Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma
Health Canada has issued a notice of compliance (NOC) for Johnson & Johnson’s (J&J) CARVYKTI (ciltacabtagene autoleucel), making it the…
Oncology
-
-
Genprex links with University of Michigan on lung cancer treatment
Genprex has entered an exclusive licensing agreement with the US University of Michigan for lung cancer therapy, Reqorsa. The company…
-
Kura Oncology partners Kyowa Kirin to advance AML treatment
Kura Oncology has partnered Kyowa Kirin in a strategic global collaboration to develop and commercialise oral ziftomenib, an investigational menin…
-
Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab
Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab, a new trifunctional bi-specific monoclonal antibody treatment for…
-
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso (osimertinib) for approval in…
-
FDA approves Syndax’s Revuforj to treat leukaemia
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or refractory (R/R) acute…
-
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination…
-
FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only nilotinib formulation that…
-
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa…
-
Kronos mulls ‘strategic alternatives’ after axing cancer drug development
Kronos Bio has discontinued the development of its last remaining clinical asset, istisociclib (KB-0742), after a review of the safety…
